Assenagon Asset Management S.A. Acquires 3,733 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK)

Assenagon Asset Management S.A. boosted its holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK) by 7.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,745 shares of the biotechnology company’s stock after acquiring an additional 3,733 shares during the quarter. Assenagon Asset Management S.A. owned 0.35% of Anika Therapeutics worth $1,253,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Eastern Bank purchased a new stake in shares of Anika Therapeutics in the 3rd quarter worth $28,000. Lazard Asset Management LLC purchased a new position in shares of Anika Therapeutics during the first quarter valued at about $180,000. State Board of Administration of Florida Retirement System purchased a new position in shares of Anika Therapeutics during the first quarter valued at about $198,000. SG Americas Securities LLC grew its position in shares of Anika Therapeutics by 7.8% during the first quarter. SG Americas Securities LLC now owns 8,615 shares of the biotechnology company’s stock valued at $219,000 after purchasing an additional 627 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its position in shares of Anika Therapeutics by 16.9% during the first quarter. BNP Paribas Financial Markets now owns 22,240 shares of the biotechnology company’s stock valued at $565,000 after purchasing an additional 3,217 shares in the last quarter. 91.53% of the stock is owned by institutional investors.

Anika Therapeutics Trading Down 3.4 %

Shares of NASDAQ:ANIK opened at $16.53 on Friday. Anika Therapeutics, Inc. has a 12 month low of $16.00 and a 12 month high of $29.11. The company has a 50-day moving average price of $24.62 and a 200 day moving average price of $25.64. The company has a market cap of $244.64 million, a price-to-earnings ratio of -3.26 and a beta of 0.83.

Anika Therapeutics (NASDAQ:ANIK) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.24). The business had revenue of $41.92 million during the quarter, compared to the consensus estimate of $39.90 million. Anika Therapeutics had a negative net margin of 44.45% and a positive return on equity of 0.94%. During the same period in the previous year, the business posted ($0.06) EPS. As a group, equities analysts forecast that Anika Therapeutics, Inc. will post -0.1 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Barrington Research cut their price objective on Anika Therapeutics from $37.00 to $25.00 and set an “outperform” rating for the company in a research report on Friday.

Anika Therapeutics Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.